Vigabatrin, tiagabine, and visual fields

Journal of Neurology Neurosurgery and Psychiatry

Volumn 74, Issue 3, 2003, Pages 286-

  Lawden, M C ^a  

^a LEICESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRATE AMINOTRANSFERASE; 4 AMINOBUTYRIC ACID; ANTICONVULSIVE AGENT; CARBAMAZEPINE; PHENYTOIN; PROGABIDE; TIAGABINE; VALPROIC ACID; VIGABATRIN;

4 AMINOBUTYRIC ACID UPTAKE; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG MECHANISM; ELECTRORETINOGRAPHY; EPILEPSY; EYE TOXICITY; GABAERGIC SYSTEM; HUMAN; MONOTHERAPY; NONHUMAN; PERIMETRY; PRIORITY JOURNAL; RETINA; SHORT SURVEY; SYNAPSE; VISUAL FIELD; VISUAL FIELD DEFECT;

ANTICONVULSANTS; EPILEPSY; HUMANS; NIPECOTIC ACIDS; RETINA; TIME FACTORS; VIGABATRIN; VISUAL FIELDS;

EID: 0037371295     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.74.3.286     Document Type: Short Survey

References (4)

1. Krauss GL, Johnson MA, Sheth S, et al. Controlled study comparing visual function in patients treated with vigabatrin and tiagabine. J Neurol Neurosurg Psychiatry 2003;74:339-43.
2. Baulac M, Nordmann JP, Lanoé Y. Severe visual-field constriction and side-effects of GABA-mimetic antiepileptic agents. Lancet 1998;352:546.
3. Beran RG, Hung A, Plunkett M, et al. Predictability of visual field defects in patients exposed to GABAergic agents, vigabatrin or tiagabine. Neurology 1999;52(Suppl. 2):A249.
4. Nousiainen I, Mäntyjärvi M, Kälviäinen R. Visual function in patients treated with GABAergic anticonvulsant drug tiagabine. Clinical Drug Investigation 2000;20:393-400.